Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (182)	11/20/2003 2:35:15 AM
From: Icebrg	Read Replies (2) \| Respond to of 363

No, not necessarily. The results are very eagerly awaited, so a CC is not out of place. But results may well be negative and in line with results seen with Evista. Evista was approved despite the negative results from their preclinical cancer study. I held some shares for a brief period but sold because of the extraordinary number of form 4s issued. It seems as if everyone in management and the BoD sold shares at least once during the autumn. If the cancer study against expectations should turn out positive it would be a huge advantage for NPSP as Preos would get a very strong selling point against Evista. Erik